Medical Innovations Group

medicalinnovations.co.uk

Medical Innovations Group designs and manufactures medical equipment for a diverse range of markets - from Hospitals and Emergency Services to the Armed Forces. All products are developed under tight quality-controlled conditions and have undergone extensive testing and trials. As a result, they meet the highest possible quality and regulatory standards.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

PDS BIOTECH REPORTS AN INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

PDS Biotechnology Corporation | December 27, 2021

news image

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS ...

Read More

MEDTECH

FLAMINGO THERAPEUTICS EXPANDS ALLIANCE WITH IONIS PHARMACEUTICALS TO DEVELOP RNA-TARGETED THERAPIES FOR ONCOLOGY

Flamingo Therapeutics, Inc. | September 09, 2021

news image

Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer. This alliance is an expansion of an existing collaboration with Ionis on the FLAME™ discovery engine, following Flamingo's Series A financing in 2020. The agreement and discovery alliance will leverage Flamingo's de...

Read More

INDUSTRIAL IMPACT

ENTERIS BIOPHARMA COMPLETES MANUFACTURING FACILITY EXPANSION AND ANNOUNCES THE LAUNCH OF CDMO BUSINESS SEGMENT

Enteris BioPharma | May 04, 2021

news image

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation, announced today the expansion of its Boonton, NJ manufacturing facility and the launch of its CDMO business segment, which provides custom solutions for the formulation, growth, and manufacturing of pharmaceuticals. Enteris also offers bench to market facilities, such as the development, manufacturing, monit...

Read More

MEDTECH

SEEGENE DEVELOPS WORLD'S FIRST COVID-19 DIAGNOSTIC VARIANT TEST CAPABLE OF IDENTIFYING MULTIPLE MUTANT VARIATIONS

Seegene | February 01, 2021

news image

South Korea's biotechnology firm Seegene (KQ096530) said Monday it built up the world's first COVID-19 diagnostic variation test, fit for screening COVID-19 and recognizing various mutant variations in a single reaction. Seegene's new variation test, the 'Allplex™ SARS-CoV-2 Variants I Assay,' can detect and separate virus variations, including those discovered to be more contagious and fatal. The new variation test identifies COVID-1...

Read More
news image

CELL AND GENE THERAPY

PDS BIOTECH REPORTS AN INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

PDS Biotechnology Corporation | December 27, 2021

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS ...

Read More
news image

MEDTECH

FLAMINGO THERAPEUTICS EXPANDS ALLIANCE WITH IONIS PHARMACEUTICALS TO DEVELOP RNA-TARGETED THERAPIES FOR ONCOLOGY

Flamingo Therapeutics, Inc. | September 09, 2021

Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer. This alliance is an expansion of an existing collaboration with Ionis on the FLAME™ discovery engine, following Flamingo's Series A financing in 2020. The agreement and discovery alliance will leverage Flamingo's de...

Read More
news image

INDUSTRIAL IMPACT

ENTERIS BIOPHARMA COMPLETES MANUFACTURING FACILITY EXPANSION AND ANNOUNCES THE LAUNCH OF CDMO BUSINESS SEGMENT

Enteris BioPharma | May 04, 2021

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation, announced today the expansion of its Boonton, NJ manufacturing facility and the launch of its CDMO business segment, which provides custom solutions for the formulation, growth, and manufacturing of pharmaceuticals. Enteris also offers bench to market facilities, such as the development, manufacturing, monit...

Read More
news image

MEDTECH

SEEGENE DEVELOPS WORLD'S FIRST COVID-19 DIAGNOSTIC VARIANT TEST CAPABLE OF IDENTIFYING MULTIPLE MUTANT VARIATIONS

Seegene | February 01, 2021

South Korea's biotechnology firm Seegene (KQ096530) said Monday it built up the world's first COVID-19 diagnostic variation test, fit for screening COVID-19 and recognizing various mutant variations in a single reaction. Seegene's new variation test, the 'Allplex™ SARS-CoV-2 Variants I Assay,' can detect and separate virus variations, including those discovered to be more contagious and fatal. The new variation test identifies COVID-1...

Read More